Evidence map›Paper›PMID 37228173›Full record

ArticleHaemophilia : the official journal of the World Federation of Hemophilia2023

Acceptability of prenatal diagnosis and prenatal treatment of haemophilia using cell and gene therapies within US haemophilia community.

Quan D M Pham, Sharon M Thomson, Burk N Schaible, Kevin D Mills, Anthony Atala, Christopher D Porada, Graça Almeida-Porada

Open access · hybridAbstract read
In one paragraph

Article in Haemophilia : the official journal of the World Federation of Hemophilia, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
1.5field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 5 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Article
  5. Carbon quantum dots in bioimaging and biomedicines.Frontiers in bioengineering and biotechnology · 2023
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 1 country.

Quan D M PhamWake Forest Institute for Regenerative Medicine, Fetal Research and Therapy Program, Wake Forest School of Medicine (WFSOM), Winston Salem, North Carolina, USA.
Sharon M ThomsonWake Forest Institute for Regenerative Medicine, Fetal Research and Therapy Program, Wake Forest School of Medicine (WFSOM), Winston Salem, North Carolina, USA.
Burk N SchaibleCenter for Research in Obstetrics and Gynecology, WFSOM, Winston Salem, North Carolina, USA.
Kevin D MillsNational Hemophilia Foundation, New York, New York, USA.
Anthony AtalaWake Forest Institute for Regenerative Medicine, Fetal Research and Therapy Program, Wake Forest School of Medicine (WFSOM), Winston Salem, North Carolina, USA.
Christopher D PoradaWake Forest Institute for Regenerative Medicine, Fetal Research and Therapy Program, Wake Forest School of Medicine (WFSOM), Winston Salem, North Carolina, USA.
Graça Almeida-PoradaWake Forest Institute for Regenerative Medicine, Fetal Research and Therapy Program, Wake Forest School of Medicine (WFSOM), Winston Salem, North Carolina, USA.ORCID https://orcid.org/0000-0002-6715-865X
Forest Institute · USNational Hemophilia Foundation · USWinston-Salem/Forsyth County Schools · US

Funding

Prenatal Cell and Gene Therapy for Hemophilia AR01HL135853 · NHLBI · WAKE FOREST UNIVERSITY HEALTH SCIENCES · PI ALMEIDA-PORADA, GRACA DUARTE, PORADA, CHRISTOPHER D · 2017 to 2020
$2.8M
cGMP Manufacture Of FVIII-Expressing Placental Cells For Hemophilia AU01HL148681 · NHLBI · WAKE FOREST UNIVERSITY HEALTH SCIENCES · PI Graca Duarte Almeida-Porada · 2019 to 2026
$1.6M
NHLBI NIH HHS HL135853NHLBI NIH HHS HL148681NHLBI NIH HHS R01 HL135853NHLBI NIH HHS U01 HL148681
6 · The paper itself

Abstract

backgroundThe overall burden of disease in persons with haemophilia continues to be high despite the latest advancements in therapeutics. Clinical trials testing prenatal treatments for several genetic disorders are underway or are recruiting subjects, attesting to the much-needed change in paradigm of how patients with monogenic disorders can be treated. Here we investigate the overall attitude towards prenatal diagnosis, preferences on types of prenatal therapies for haemophilia, the level of 'acceptable' risk tolerated, and which social and moral pressures or disease personal experiences may predict willingness of individuals to consider foetal therapy in a future pregnancy.

resultsA multidisciplinary team designed the survey, and the study was carried out using REDCap, and publicized through the National Haemophilia Foundation. Subjects ≥18 years of age were eligible to participate in the study. We assessed participants' attitudes towards prenatal therapy and their level of 'acceptable' risk towards the procedure and therapy. The survey was completed by 67 adults, the majority females. Respondents were willing to undergo prenatal diagnosis, and their main concerns related to the well-being of the pregnant woman and the foetus regarding lasting therapeutic efficacy, side effects of the therapy, and procedural risks, but they were likely to accept a wide range of prenatal therapeutic options, particularly if the foetal therapy proved to be long-lasting and safe.

conclusionsThese data demonstrate the willingness of persons with haemophilia, and the haemophilia community, to explore new treatment options beyond the currently offered approaches.

Indexed as

Hemophilia AAdultFemaleHumansPregnancyPrenatal DiagnosisSurveys and Questionnairesclinical implicationsfoetal cell therapyfoetal gene therapyhaemophiliapatient attitudessocial implications

Identifiers

PMID37228173
PMCPMC10524589
OpenAlexW4378194800

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.